Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
Colombo
YEYE 3 in 1 Instant Coffee Mix 50 Sachet
Romeshka
Updated:
Yesterday at 12:16 AM
Colombo
Red Hat Certified System Administrator (RHCSA) - RHEL 10
Sanjeewani95
Updated:
Friday at 7:43 PM
NURSING , CAREGIVER , HOTEL & BEAUTY COURSES
IVA Para Medical Campus
Updated:
Jul 2, 2026
Handmade Character Soft Toys Peppa Pig Family
anil1961
Updated:
Jul 1, 2026
Ad icon
Video Content Creator
pramukag
Updated:
Jun 28, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
ElaKiri.com
News and Updates
MHRA (UK) approves Nuvaxovid
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 27345185" data-attributes="member: 562115"><p>Nuvaxovid, the COVID-19 vaccine developed by Novavax, has just been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA). Thus it becomes the fifth Covid vaccine approved in the UK.</p><p></p><p>Professor Sir Munir Pirmohamed, Chair of the independent Commission on Human Medicines, said:</p><p></p><p>"The independent Commission on Human Medicines and its COVID-19 Expert Working Group has carefully considered the available evidence on safety, quality and effectiveness. We are pleased to say that we have advised that the benefit risk balance of Nuvaxovid is positive.</p><p>Nuvaxovid is distinct from other COVID-19 vaccines currently in use in the UK as it uses recombinant protein-based technology which has been used for many years in the development of vaccines to prevent other illnesses, for example Hepatitis B. In reaching its decision, the MHRA considered the results of 2 large clinical trials involving nearly 50,000 participants."</p><p></p><p>PS: Nuvaxovid is the Covid vaccine develped by Novavax. Basically it uses Moth Cells & Tree bark. Unlike mRNA (Pfizer & Moderna) or Viral-Vector (Sputnik & AZ), the Nuvaxovid is a <strong>Protein Subunit Vaccine.</strong></p><p>It contains a protein (<strong>from Moth cells</strong>) plus an adjuvant named <strong>Matrix-M, </strong>which is based on a <strong>saponin extracted from the soapbark tree (Quillaja saponaria).</strong></p><p>Using the Matrix-M adjuvant, a <strong>smaller dose of spike protein achieves the desired immune response.</strong></p><p></p><p>The vaccines has <strong>no genetic material - only proteins</strong>. It's just like a traditional protein based Flu vaccine. Once again, this vaccine too is <strong>based on the Spike protein </strong>and thus could work differently with the variants. However, Novavax claims that vaccine is effective in generating an immune response against the Omicron variant,</p><p>They also say that they are already developing an <strong>Omicron-specific vaccine</strong> and expects to begin manufacturing doses of the variant-specific shot very soon.</p><p></p><p>Nuvaxovid will be given as two separate 0.5 mL injections, three weeks apart. It's approved only for those above 18 years of age.</p></blockquote><p></p>
[QUOTE="imhotep, post: 27345185, member: 562115"] Nuvaxovid, the COVID-19 vaccine developed by Novavax, has just been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA). Thus it becomes the fifth Covid vaccine approved in the UK. Professor Sir Munir Pirmohamed, Chair of the independent Commission on Human Medicines, said: "The independent Commission on Human Medicines and its COVID-19 Expert Working Group has carefully considered the available evidence on safety, quality and effectiveness. We are pleased to say that we have advised that the benefit risk balance of Nuvaxovid is positive. Nuvaxovid is distinct from other COVID-19 vaccines currently in use in the UK as it uses recombinant protein-based technology which has been used for many years in the development of vaccines to prevent other illnesses, for example Hepatitis B. In reaching its decision, the MHRA considered the results of 2 large clinical trials involving nearly 50,000 participants." PS: Nuvaxovid is the Covid vaccine develped by Novavax. Basically it uses Moth Cells & Tree bark. Unlike mRNA (Pfizer & Moderna) or Viral-Vector (Sputnik & AZ), the Nuvaxovid is a [B]Protein Subunit Vaccine.[/B] It contains a protein ([B]from Moth cells[/B]) plus an adjuvant named [B]Matrix-M, [/B]which is based on a [B]saponin extracted from the soapbark tree (Quillaja saponaria).[/B] Using the Matrix-M adjuvant, a [B]smaller dose of spike protein achieves the desired immune response.[/B] The vaccines has [B]no genetic material - only proteins[/B]. It's just like a traditional protein based Flu vaccine. Once again, this vaccine too is [B]based on the Spike protein [/B]and thus could work differently with the variants. However, Novavax claims that vaccine is effective in generating an immune response against the Omicron variant, They also say that they are already developing an [B]Omicron-specific vaccine[/B] and expects to begin manufacturing doses of the variant-specific shot very soon. Nuvaxovid will be given as two separate 0.5 mL injections, three weeks apart. It's approved only for those above 18 years of age. [/QUOTE]
Insert quotes…
Verification
Nawa warak dahaya keeyada? (Namaya wadi kireema dahaya)
Post reply
Top
Bottom